- Home
- RNTX vs VRAR Comparison
RNTX vs VRAR Comparison
Compare RNTX & VRAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- VRAR
- Stock Information
- Founded
- RNTX 2001
- VRAR 2016
- Country
- RNTX United States
- VRAR United States
- Employees
- RNTX N/A
- VRAR N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- VRAR Retail: Computer Software & Peripheral Equipment
- Sector
- RNTX Health Care
- VRAR Technology
- Exchange
- RNTX Nasdaq
- VRAR Nasdaq
- Market Cap
- RNTX 28.0M
- VRAR 29.1M
- IPO Year
- RNTX N/A
- VRAR 2021
- Fundamental
- Price
- RNTX $1.15
- VRAR $1.48
- Analyst Decision
- RNTX Hold
- VRAR Strong Buy
- Analyst Count
- RNTX 1
- VRAR 1
- Target Price
- RNTX N/A
- VRAR $2.62
- AVG Volume (30 Days)
- RNTX 133.3K
- VRAR 119.5K
- Earning Date
- RNTX 11-13-2025
- VRAR 11-13-2025
- Dividend Yield
- RNTX N/A
- VRAR N/A
- EPS Growth
- RNTX N/A
- VRAR N/A
- EPS
- RNTX N/A
- VRAR N/A
- Revenue
- RNTX N/A
- VRAR $8,756,789.00
- Revenue This Year
- RNTX N/A
- VRAR $23.96
- Revenue Next Year
- RNTX N/A
- VRAR $12.15
- P/E Ratio
- RNTX N/A
- VRAR N/A
- Revenue Growth
- RNTX N/A
- VRAR N/A
- 52 Week Low
- RNTX $1.04
- VRAR $0.50
- 52 Week High
- RNTX $4.40
- VRAR $7.00
- Technical
- Relative Strength Index (RSI)
- RNTX 45.62
- VRAR 54.01
- Support Level
- RNTX $1.07
- VRAR $1.44
- Resistance Level
- RNTX $1.25
- VRAR $1.57
- Average True Range (ATR)
- RNTX 0.14
- VRAR 0.10
- MACD
- RNTX -0.01
- VRAR 0.01
- Stochastic Oscillator
- RNTX 21.33
- VRAR 64.00
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.